AbCellera’s Post

VERZENIO (abemaciclib) is an oral, continuously dosed, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of metastatic and high-risk early-stage HR , HER2- breast cancer. At the American Society of Clinical Oncology (ASCO) 2024 meeting Eli Lilly and Company reported findings from the Phase III study (CYCLONE 2) of VERZENIO (abemaciclib) with ZYTIGA (abiraterone) in patients with mCRPC. DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: Unlock Expert Insights and In-Depth Analysis! https://lnkd.in/ggPcVGZ7 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

In the rapidly evolving landscape of cancer therapeutics, the potential of T-cell receptor (TCR) therapy in treating solid tumors has gained significant attention. The below article delves into the cutting-edge developments and innovative strategies employed to enhance the efficacy of TCR-T (T-cell receptor engineered T-cell) therapy for solid malignancies. Read the full article here: https://lnkd.in/ebE3CM9D #OrangeCountyBio, #OCBio, #T-cell, #TCR, #TCR-T, #CellTherapy, #GCT, #CellandGeneTherapy

[Clinical Trials] BriaCell Therapeutics Corp.'s phase 3 trial of Bria-IMT shows 71% intracranial objective response rate in metastatic breast cancer ➡️https://lnkd.in/gwWEfPt2 Clover Biopharmaceuticals phase 1 trial of SCB-219M shows 100% platelet count maintenance post-chemotherapy at 1-week in Thrombocytopenia ➡️https://lnkd.in/gVMNKKNy

🚨 🥁🥁🥁New FDA Approval 👉🏼Today the US FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy @FDAOncology #SCLC 🎯 ⭐️Tarlatamab = bispecific T-cell engager (BiTE), a two-armed drug that simultaneously latches onto tumor cells and T cells, bringing them close together and helping the T cells recognize and destroy cancer cells https://lnkd.in/eTXAdS85

Atossa Therapeutics, Inc. (NASDAQ:ATOS) President & CEO Dr. Steven Quay joins Thomas Warner from Proactive to speak about the latest developments in his and the clinical-stage #biopharma company's fight against #BreastCancer. Dr. Quay gives an overview of ongoing clinical trials centered around their innovative drug, oral #Endoxifen. The drug combines oestrogen receptor degradation, suppression, and PKC beta inhibition to combat breast #cancer. The trials are conducted at different stages of breast cancer management. One focus is on breast cancer prevention, specifically targeting high mammographic breast density, a significant risk factor. Watch at #Proactive #ProactiveInvestors #NASDAQ #ATOS #AtossaTherapeutics #Atossa http://ow.ly/HLNh104RRTz

LABN Trending News: FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER https://lnkd.in/gsKeN3mU Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host [...]

Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer: Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors. #finance #pharmacy #lifesciences

Early #diagnostic of #pancreaticcancer : 2 important announces this week from Immunovia AB and City of Hope Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study https://lnkd.in/gm_ncUNy An Exosome-based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer https://lnkd.in/dj5CZUB6 However, predictive diagnostics developed by ACOBIOM are needed to target 1st line therapies (#gemcitabine, #FOLFIRINOX). For more information: https://lnkd.in/gFGE6-AW

Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER breast cancer models https://lnkd.in/gQ-QaNY3

Last week, our CEO Ben Zeskind, Ph.D. sat down with Caroline Hopkins at Precision Oncology News, to discuss the recent progress with our lead product candidate, IMM-1-104. From IMM-1-104's fast-track designation for patients with pancreatic cancer who have failed one line of treatment, to dosing our first patient in the Phase 2 portion of the ongoing IMM-1-104 Phase 1/2a clinical trial, to reporting positive preliminary data from the Phase 1 portion of that trial Read more about our differentiated approach to cancer research and next steps with IMM-1-104.https://buff.ly/4cvtRd2